Filing Flows › 8-K events › Manhattan Associates
Manhattan Associates: completion of an acquisition or disposition of assets
Form 8-K filed Oct 27, 2026 · items 2.01, 3.03, 5.02, 5.03, 7.01
BuybacksManhattan Associates Reports Third Quarter Results
What the filing says
Manhattan Associates Reports Third Quarter Results ATLANTA – October 27, 2026 – Leading Supply Chain and Omnichannel Commerce Solutions provider Manhattan Associates, Inc. (NASDAQ: MANH) today reported revenue of $306.2 million for the third quarter ended September 30, 2026, compared to $275.8 million in Q3 2025.
ScaleThe filing names $306.2M: about 25% of Manhattan Associates' annual revenue ($1.22B, four times the latest quarter).
Read the filing on SEC EDGAR →
What usually followsAcross 2,671 8-Ks reporting Item 2.01 (completed acquisition or disposition) in our universe, the stock's median move the next session was +0.1% (typical size ±1.6%, up 52% of the time); over the following 21 sessions, +1.2%. Item 3.03: +0.1% next session across 1,456. Item 5.02: −0.1% next session across 39,174. Every item ranked →
What this kind of filing means
Item 2.01 — Completion of an acquisition or disposition of assets. Completing an acquisition or a sale changes the company’s size and mix from this quarter on; the price paid and how it was financed are in the filing.
Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.
Manhattan Associates at a glance
Manhattan Associates, Q3 2026: revenue $306M (+11% year over year), operating margin 26.5%. The chart follows the revenue to costs, profit and cash.
Manhattan Associates: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent buybacks
- Kontoor Brands Nov 6, 2026
- Align Technology Nov 6, 2026
- Concentra Group Holdings Parent Nov 5, 2026
- HF Sinclair Nov 5, 2026
- 1stdibs.com Nov 5, 2026
- Inogen Nov 5, 2026
- Diodes Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
- Adient Nov 4, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.